Toremifene does not control prostatic intraepithelial neoplasia
NEW YORK (Reuters Health) - High-grade prostatic intraepithelial neoplasia (HGPIN) puts men at
relatively high risk for prostate cancer, and treatment with toremifene did not reduce that risk in a phase III
trial.
Source: Modern Medicine - Category: Journals (General) Source Type: news